6505--Droxidopa Capsules (VA-27-00007975)

The VA, DoD, IHS, BOP, and FHCC are conducting market research for a future national mandatory‑requirements contract to supply Droxidopa capsules (100 mg, 200 mg, 300 mg) in 90‑count bottles. The contract will be awarded on a base‑year plus up to four option years basis, with an estimated total annual usage of 13,485 bottles across three strengths. Respondents must provide unique National Drug Codes, confirm manufacturing or supply commitments, and demonstrate compliance with VA’s unit‑of‑use packaging specifications (child‑proof caps, 120 cc bottle, label dimensions). The deadline for questionnaire responses is September 4 2026. • Product: Droxidopa oral capsules (100 mg, 200 mg, 300 mg) – 90‑count bottles. • Estimated annual volume: 6,160 (100 mg) + 3,587 (200 mg) + 3,738 (300 mg) = 13,485 bottles. • Contract structure: 1‑year base period with up to four 1‑year options (maximum 5 years). • Mandatory packaging: child‑proof safety cap, 120 cc cylindrical bottle, label 5.25” × 2”. • Requirements: unique NDC, manufacturer letter of commitment (if not the manufacturer), PPV charge‑back agreements, small‑business status disclosure, U.S.–made or TAA‑eligible product confirmation. • Response deadline: September 4 2026, 2:30 PM Central Time. • Point of contact: Andrew Cazares, Contract Specialist, VA (email & phone provided).